



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2025 #13

April 14, 2025

INSIDE:

- Blood Community Comments in Response to HCT/Ps Guidances...2
- REGULATORY NEWS....2
- WORD IN WASHINGTON2
- BRIEFLY NOTED.....3
- Register for the ABC Advocacy Summit.....4
- Nominations Are Open for HOSA Partnership Recognition4
- Participate in the ABC Economic Outlook Survey4
- April ADRP Webinar: Conference 2025 "Know Before You Go"5
- 2025 ADRP Annual Conference Room Block Closing April 18th5
- RESEARCH IN BRIEF5
- INFECTIOUS DISEASE UPDATES6
- MEMBER NEWS.....6
- GLOBAL NEWS7
- COMPANY NEWS7
- CALENDAR.....8
- POSITIONS.....9

Blood Community Letter to FDA Regarding HTLV-I/II Recommendations

America’s Blood Centers, the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross have sent a [joint letter](#) to the U.S. Food and Drug Administration (FDA) urging the agency to reconsider the current testing requirements for human T-lymphotropic virus types I and II (HTLV-I/II).

Specifically, the blood community requested revisions to the recommendations due to:

- “the declining prevalence of HTLV-I/II infection in U.S. blood donors;
- the low incidence observed among U.S. repeat blood donors;
- the low likelihood of infection and disease in individuals receiving HTLV-I/II antibody-reactive whole blood and blood components;
- the efficacy of leukoreduction in reducing the infectivity of HTLV-I/II antibody-reactive donations; and
- the use of effective pathogen reduction technology (PRT) for some platelets.”

ABC, AABB, and the American Red Cross further explained that, “the elimination of universal HTLV-I/II antibody testing is a first step in an ongoing dialogue of how to streamline the qualification of blood donations that maintains safety while eliminating unnecessary testing.”

HTLV-I and II are, “retroviruses transmitted from mother to child at birth and/or via breast milk, sexually (with more efficient transmission from male to female), and through intravenous drug use and other blood exposure. They may also be transmitted via transfusion of cellular blood components but ha[ve] not been demonstrated to be transmitted by plasma. HTLV is a strict intraleukocytic agent. Therefore, leukoreduction is highly efficient at preventing transmission from cellular blood components containing residual lymphocytes.”

(Source: Blood Community HTLV-I and II FDA [Joint Letter](#), 3/26/25) 💧



Blood Community Comments in Response to HCT/Ps Guidances

America's Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross have provided joint comments to the U.S. Food and Drug Administration (FDA) regarding two final guidances: [Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by y Human Cells, Tissues, and Cellular and Tissue-Based Products \(HCT/Ps\)](#), and [Recommendations to Reduce the Risk of Transmission of *Mycobacterium tuberculosis* \(Mtb\) by HCT/Ps](#).

In the [sepsis comments](#), the blood community expressed support for “FDA’s dedication and mission to enhance the safety of HCT/Ps and to prevent the transmission of communicable disease agents linked to sepsis.” Additionally, ABC, AABB, and the American Red Cross asked for clarification on screening for pathogens that may cause sepsis, and what constitutes a “suspicion of sepsis.”

The [Mtb joint comments](#) asked for several clarifications, including clarifying, “that donor testing is not recommended at this time.” 💧

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) has canceled the licensure workshop that was planned to be held in September through a Public Webinar titled “FDA Review of Biologics License Applications for Blood and Source Plasma.” The virtual event was, “intended to provide blood establishments and other stakeholders with an overview of the Office of Blood Research and Review’s (OBRR) approach to the review of biologics license applications for the manufacture of blood and blood components, including source plasma.” America’s Blood Centers (ABC) previously requested that FDA hold such an event to address challenges raised by ABC members. 💧

WORD IN WASHINGTON

Rep. Suhas Subramanyam (D-Va.) [recognized](#) Inova Blood Donor Services, a member of America’s Blood Centers, platelet donor Richard Martin during a House floor speech for making his 700th platelet donation. He explained that Mr. Martin’s commitment, “isn’t just a number, it represents lives saved and hope restored. [Today,] we celebrate Richard’s altruistic spirit and dedication as a platelet donor. He’s a shining example of what it means to serve one’s neighbors and community.” Last month, *WTOP News* [reported](#) that the milestone made Mr. Martin Inova’s highest active platelet donor. Mr. Martin told the news outlet that he began donating, “whole blood with the Red Cross and then switched to Inova when he was asked to consider a different type of donation in 1982. His father donated 17 gallons of whole blood, and Martin tried to reach that same achievement, but only made it to seven when he was asked about donating platelets. [Mr. Martin] considered it the major leagues of blood donations and was eager to start. At that time, the process involved donating from both arms. He’s continued to donate platelets ever since, visiting Inova’s Blood Donor Service Center in Sterling, Virginia, every two weeks.”



(Sources: Rep. Subramanyam [House Floor Speech](#), 4/8/25; *WTOP News*, “[This Virginia man has donated platelets 700 times and he isn’t planning to stop](#),” 3/5/25)

(continued on page 3)

WORD IN WASHINGTON (continued from page 2)

Tracy Beth Høeg, MD, PhD has been [named](#) as a special assistant to U.S. Food and Drug Administration (FDA) Commissioner Martin Makary, MD, MPH. According to a report from *MedPage Today*, Dr. Høeg is a sports medicine physician and epidemiologist who, “holds a medical license in California, where she is listed as a physician at Northern California Orthopaedic Associates. She also has conducted epidemiological research at institutions including the University of California San Francisco and the Massachusetts Institute of Technology’s Sloan School of Management. Dr. Høeg completed her medical degree at the Medical College of Wisconsin in 2006, and her doctor of Philosophy degree in public health and epidemiology at the University of Copenhagen in 2014.”

(Source: *MedPage Today*, “[New advisor to FDA chief pushed back on COVID Policies](#),” 4/8/25) 💧

BRIEFLY NOTED

A [letter](#) has been sent to U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed by more than 90 organizations, including the American Society of Hematology (ASH), urging him to, “fully restore the Centers for Disease Control and Prevention’s (CDC) Division of Blood Disorders and Public Health Genomics.” The groups explain in the letter that, “[t]he Division drives critical life- and cost-saving advances in care and prevention for people with these conditions and supports blood and blood product safety monitoring activities of national importance. The Division’s work traces back to the 1980s’ tainted blood crisis, when an estimated 90% of the U.S. hemophilia population contracted HIV and/or hepatitis C through the use of plasma-derived clotting factor products. CDC investigators were the first to discern and warn of HIV’s transmissibility through blood. To this day, the Division of Blood Disorders serves the bleeding disorders community and the nation at large through its public health surveillance activities – including maintaining a laboratory with blood samples dating back to 1996 to which additional samples are added still today. The Division also funds the collection and dissemination of key data on bleeding disorders through the collaborative ‘Community Counts’ program and supports educational outreach to increase patient and provider understanding of hemophilia and its complications. Recently, the CDC’s work has focused on improving knowledge about and prevention of inhibitors – a devastating and expensive complication of hemophilia that vastly increases the burden of disease and costs of treatment.”

(Source: ASH [News Release](#), 4/8/25) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2025 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry
 Chief Medical Officer: Jed Gorlin
 Editor: Mack Benton
 Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$420

Send subscription queries to memberservices@americasblood.org
 America’s Blood Centers
 1717 K St. NW, Suite 900, Washington, DC 20006
 Phone: (202) 393-5725
 Send news tips to newsletter@americasblood.org.



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Register for the ABC Advocacy Summit

[Registration](#) is open for America's Blood Centers (ABC) [Advocacy Summit](#). This event will take place in Washington, D.C. at the Hamilton Hotel June 10th-11th. [Book your room](#) before Thursday, May 15th to take advantage of the discounted rate. The [full agenda](#) is available and don't miss this opportunity to let your voice be heard as this event connects the blood community with national leaders in public policy and advocacy including meetings with members of Congress and their staff. Join us for a full day of advocacy training and group preparations for meetings with congressional offices on June 10th before heading to Capitol Hill on June 11th for group meetings with members of Congress and their staff. ABC will coordinate and schedule meetings on behalf of all attendees and conclude the day with a reception for all attendees. The training will feature insights from former members of Congress, seasoned lobbyists, and public policy staff from partner organizations, and ABC's government affairs team. Please [contact us](#) with questions.

Nominations Are Open for HOSA Partnership Recognition

ABC encourages member blood centers to [submit nominations](#) recognizing the HOSA-Future Health Professionals chapters that they are partnering with. The submission deadline is May 15th as the nomination-based categories highlight outstanding contributions from HOSA chapters and state associations in strengthening the nation's blood supply during times of critical need and/or through support of blood donation or a blood drive. The winning HOSA chapters will be honored at the [HOSA International Leadership Conference](#) in June. More information is available [here](#). Also, please remind your HOSA student partners to [upload](#) their blood donation data for the 2024-25 school year by May 15th. The goal is to surpass last year's [33,000 donor record](#), and your support is crucial in achieving this. For more information on data submission and our HOSA partnership, please visit www.AmericasBlood.org/HOSA.

Participate in the ABC Economic Outlook Survey

The [ABC Economic Outlook Survey](#) is open. This resource provides a comprehensive look at blood center finances, including 19 of the most frequently used ratios for benchmarking the financial health of an organization as well as median service fees for 30 different blood products and blood center procedures. The aggregate data from this survey is important to both members and ABC as we advocate for fair and accurate reimbursement policies. Survey results are anonymized and aggregated, and all reporting complies with antitrust requirements. The ability to download final trend reports and create customized reports based on selected filters will be available to participants via ABC's benchmarking portal. Please [contact us](#) with questions.

(continued on page 5)



INSIDE ABC (continued from page 4)

April ADRP Webinar: Conference 2025 "Know Before You Go"

[Registration](#) is open for the April 16th ADRP webinar at 1 p.m. EDT titled [Conference 2025 "Know Before You Go."](#) Hear members of the ADRP Conference Committee share highlights of the conference schedule and events including insights into how you can maximize your experience at conference.

2025 ADRP Annual Conference Room Block Closing April 18th

[Register now](#) for the [2025 ADRP Annual Conference](#) in Oklahoma City, Oklahoma, from May 6th to 8th at the Omni Oklahoma City Hotel. Remember to [book your hotel room](#) by April 18th for the discounted rate. This conference offers a chance to learn about industry trends, share ideas, and connect with other donor recruitment, donor services, collections, marketing, and communications professionals. Join more than 400 of your peers by participating in pre-conference workshops, attending compelling educational sessions, engaging in roundtable discussions, and exploring an expansive exhibit hall filled with innovative solutions. [Seize this extraordinary opportunity](#) to learn, share, and grow within the blood community. 💧

RESEARCH IN BRIEF

A Survey of Massive Transfusion Policies in The Netherlands. A paper published in *Transfusion* describes a [survey](#) that was conducted to, "evaluate logistical capacity in relation to massive transfusion policy and product usage versus wastage." The researchers explained that, "[t]his survey was also initiated to evaluate the possible interest in a ready-to-use plasma product." During the period of January to April 2022, "[a] questionnaire was sent to all Dutch hospitals with transfusion capacity, [with] 69 hospitals [being] approached, [and a] total of 58 hospitals responded (84 percent)." The researchers noted that, "[a]ll responding hospitals used a massive transfusion protocol (MTP) [and most] hospitals (67 percent, n=37) transfused equal units of plasma and erythrocytes (1:1). [Three hospitals (5 percent)] reported a ratio higher than the advised maximum of two units of erythrocytes for every unit of plasma. These hospitals did neither comply with the Dutch National guidelines nor with European guidelines. All but one hospital initiated their trauma transfusion with erythrocytes; however, four hospitals claimed they would initiate transfusion with plasma if it was readily available (n=5, 10 percent)." The paper explained that, "[e]ight hospitals (15.7 percent) reported having thawed plasma (which can be stored for five days at 4°C) readily available for transfusion." The researchers noted that the study, "found no relation between plasma availability and the erythrocyte/plasma ratio described in the MTP. Thirty-five hospitals (60 percent) claimed to be interested in incorporating a ready-to-use plasma product into their transfusion strategy. [The study] found that hospitals that take [greater than] 15 min. to have plasma available for transfusion generally were more interested in a new plasma product compared with the hospitals that have plasma ready for transfusion within 15 min. (n=55, 75.0 vs. 57 percent)... The percentage of discarded units of erythrocytes was 1.2 [and the] percentage of discarded plasma units was 7.4." The authors further explained that, "[t]here was no relation between having thawed plasma readily available and the percentage of plasma wasted. There was, however, a significant relation between direct plasma availability and yearly number of transfusions, that is, the hospitals with direct plasma availability perform significantly more transfusions than the hospitals without direct plasma availability." They concluded by noting that, "[t]his was the first nationwide survey on massive transfusion practices in the Netherlands. There is uniformity when it comes to using a MTP to guide clinical practice and the [less than or equal to] 2:1 erythrocyte/plasma transfusion ratios used in the MTP. Logistics surrounding plasma availability and plasma thawing capacity do not influence MTPs;

(continued on page 6)

RESEARCH IN BRIEF (continued from page 5)

moreover, direct plasma availability did not increase plasma wastage. Nevertheless, there seems to be substantial interest in a ready-to-use plasma product, especially in low-volume hospitals with limited plasma usage.”

Citation: Van der Heiden, A.M., ter Horst, M., van Bohemen, M.R., Noorman, F., Novotny, V.M.J., Klei, T.R.L., *et al.* “[Massive transfusion policy in the Netherlands, a nationwide survey.](#)” *Transfusion*. 2025.

Contributed by Richard Gammon, MD 💧

INFECTIOUS DISEASE UPDATES

Measles

The U.S. Centers for Disease Control and Prevention (CDC) has [published](#) an update regarding measles outbreaks. As of the April 11th, there have been seven measles outbreaks (defined as three or more related cases) in the U.S. this year resulting in 712 confirmed cases, 79 hospitalizations (11 percent) and two confirmed deaths, the first in the U.S. since 2015, and another under investigation. According to the agency the cases have been reported by 25 jurisdictions: Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Indiana, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New Mexico, New York City, New York State, Ohio, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, and Washington with 93 percent of cases (660 of 712) being outbreak-associated. In 2024, the U.S. reported 285 total cases. Transfusion-transmission of measles has never been demonstrated, and any risk to the blood supply is believed to be theoretical.

Additionally, the CDC issued an April 7th [statement](#) regarding the ongoing measles outbreak explaining that, “[HHS] Secretary Kennedy’s directive is for CDC to lead the nation in health readiness and response. [His visit](#) to Texas, to support the state’s efforts to control the measles outbreak, resulted in discussions with Texas state health officials to deploy another CDC response team to the area to further assist with the state’s efforts to protect its citizens against measles and its complications.”

(Sources: CDC [Update](#), 4/11/25; CDC [Statement](#), 4/7/25) 💧

MEMBER NEWS

Vitalant has [partnered](#) with the Ventura County Fire Department on a prehospital blood program. *CBS News* reported that through the program, “rescue ambulances with whole blood, offering patients transfusions at the scene. The emergency blood transfusion program enables firefighter-paramedics to stabilize severely injured patients before arriving at the hospital.” The program launch comes in the wake of a Ventura County Fire Department analysis, “of incidents from July 2017 to July 2024 [that] showed that three to seven trauma patients per month may have benefited from the program by receiving prehospital blood transfusions.” Daniel Shepherd, medical director of the Ventura County Emergency Medical Services Agency added in the article, “[t]he addition of whole blood to our treatment protocols further narrows the gap between critical interventions performed in the hospital versus in the field. Our goal is that this will result in improved outcomes for our sickest patients.”

(Source: *CBS News*, “[Ventura County Fire Department ambulances offer emergency blood transfusions](#), 4/9/25) 💧

GLOBAL NEWS

Greece's Council of State, the country's highest administrative court, has [reversed](#) the 2022 policy shift to individual donor assessments (IDA). According to *The National Herald*, "[t]he court ruled that [the change to IDA] bypassed expert recommendations and lacked a supporting scientific study, as reported by *Kathimerini*. The ministry had lifted the prohibition on [sexually active gay and bisexual] men donating blood, which had been in place since the 1980s during the HIV crisis. The court found that the decision disregarded prior advice from two health advisory panels, which recommended time-based deferral periods — either three or 12 months — for individuals in high-risk groups." The court's decision to overturn the IDA policy shift comes in the wake of advocacy efforts from thalassemia patient groups, "who argued that the ministry failed to prioritize public health and proper blood safety protocols, which were put in place during a time when many gay men died from HIV. The court emphasized that any donor restrictions related to sexual behavior must be based on scientific and epidemiological evidence, not blanket exclusions, leaving the ministry to reevaluate the policy."

(Source: *The National Herald*, "[Greek high court reinstates 1980s ban on gay men donating blood](#)," 4/6/25)

A report in *The Korea Times* [noted](#) that South Korea is, "seeing a steady decline in the number of blood donors, with experts warning of long-term risks to the nation's blood supply as the country grapples with a low birthrate and rapidly aging population." According to the news outlet, recent data published by the Korean Red Cross revealed that, "[o]nly about 1.26 million people donated blood at least once last year, down from 1.33 million in 2022 and marking the lowest figure since national records began in 2005. The 2023 figure also dipped below the number recorded during the height of the COVID-19 pandemic in 2020 and 2021. The drop represents a 25 percent decline compared to a decade earlier, when nearly 1.7 million individuals donated blood in 2014. Despite the shrinking donor pool, the total number of donations has been sustained in part by repeat donors. The average number of donations per person rose to 2.26 last year, up from 1.8 a decade ago." Additionally, the data showed that, "people in their 20s accounted for the largest share of donations in 2023, contributing 35.5 percent of the total. They were followed by donors aged 16 to 19 (19.3 percent), those in their 40s (16.9 percent), 30s (15.9 percent), 50s (10.4 percent) and those over 60 (2.1 percent). However, donations from teenagers and people in their 20s have dropped significantly over the past decade. Among those aged 16 to 19, the annual number of donations was nearly halved over the past decade — from 1.07 million in 2014 to 550,000 last year." Officials from the Korean Red Cross hypothesize that, "the trend to both demographic shifts and policy changes. Fewer young people are available to donate due to the declining birthrate, while recent changes to university admissions criteria mean that individual volunteer activities like blood donation no longer carry weight in the application process."

(Source: *The Korea Times*, "[Korea faces declining blood donors amid low birthrate, aging population](#)," 4/7/25) ♦

COMPANY NEWS

ArtBlood and Expression Manufacturing LLC [announced](#) the signing of a memorandum of understanding (MOU), "to collaborate on the clinical development and large-scale production of *in vitro*-produced blood." According to a news release, "[t]he collaboration aims to establish a comprehensive system for clinical trials, industrial-scale production, and eventual commercialization of *in vitro*-produced red blood cells. As part of the partnership, ArtBlood will contribute its proprietary technologies and expertise in red blood cell proliferation, differentiation, purification, and quality control analytics. Meanwhile, Expression will apply its extensive experience in cGMP-compliant cell therapy manufacturing, ensuring high-quality, scalable production of BioBlood for clinical and commercial applications. Both companies will also explore

(continued on page 8)

COMPANY NEWS (continued from page 7)

joint intellectual property development and global commercialization strategies for the artificial blood market.” ArtBlood [previously](#) announced the development of BioBlood, a blood substitute, made from using stem cell *in vitro* and the company has secured 10.5 billion won (approximately \$7.3 billion) in Series A funding.

(Source: Expression Manufacturing LLC [News Release](#), 4/8/25)

Fresenius Kabi has opened nominations for the [National Blood Donation Hall of Fame](#) program. This initiative, in collaboration with blood centers, recognizes individuals who support the U.S. blood supply. It celebrates the commitment and dedication of extraordinary donors, volunteers, and advocates helping to create awareness on the need for blood and importance of blood donation. Blood centers are invited to nominate someone who exhibits a steadfast commitment to blood donation. Email nominations to: info.usa@fresenius-kabi.com by June 9th. Learn more and see past hall of fame inductees [here](#).

• **FRESENIUS KABI**
 • **National Blood Donation**
 • **Hall of Fame**

(Source: Fresenius Kabi [Announcement](#), 4/10/25)

Blood Bank Computer Systems, Inc. (BBCS) recently [announced](#) that it will be the blood establishment computer system (BECS) provider for San Diego Blood Bank, a member of America’s Blood Centers. According to a company news release, “BBCS will implement the ForLife Biologics Platform® across San Diego Blood Bank’s operations to enhance efficiency, streamline workflows, and support long-term strategic growth.”

(Source: BBCS [News Release](#), 4/8/25)

The **Advanced Medical Technology Association (AdvaMed)** [published](#) a statement in the wake of President Trump’s pause on reciprocal tariffs. Scott Whitaker, president and chief executive officer of AdvaMed, explained in the statement that, “[w]e are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medical technology (medtech) industry, which is number one globally. Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.” AdvaMed previously [sought](#) a medical technology exemption from all tariffs.

(Source: AdvaMed [News Release](#), 4/9/25) ♦

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2025

April. 7. **National Academies of Sciences, Engineering, and Medicine (NASEM) Committee on a Strategic Plan and Blueprint for Addressing Thalassemia in the United States Meeting (Virtual, Open, Public Session)**. [Registration](#) is open. More information available [here](#).

(continued on page 9)

CALENDAR (continued from page 8)

April 9. **ABC Women's Executive Leadership Community (WELC) Webinar: The Art of Facilitation and Listening: Unlocking Leadership Excellence.** More information and a link to registration are available to ABC members [here](#).

April 16. **OneBlood Educational Seminar (Virtual).** RSVP [here](#). More information available [here](#).

April 16. **ADRP Webinar: ADRP Annual Conference 2025: "Know Before You Go."** [Registration](#) is open. More information available [here](#).

May 6-8. **2025 ADRP Annual Conference. Oklahoma City, Okla.** [Registration](#) is open. More information available [here](#).

May 14-15. **International Plasma and Fractionation Association (IPFA)/Paul-Ehrlich Institut[e] (PEI) 30th International Workshop on Surveillance and Screening of Blood-borne Pathogens. Heidelberg, Germany.** [Registration](#) is open. More information available [here](#).

May 20-21. **International Plasma Protein Congress. Warsaw, Poland.** [Registration](#) is open.

June 1-4. **International Society of Blood Transfusion (ISBT) 35th Regional Congress. Milan, Italy.** [Registration](#) is open. More information available [here](#).

June 10-11. **ABC Advocacy Workshop. Washington, D.C.** More information is coming soon.

June 25-26. **HHS ODP TBDAIC Community Engagement Meeting (Hybrid). Portland, Maine.** More information is coming soon.

Sept. 24-25. **2025 ADRP Master Class: "Building Brighter Experiences: Empowering Customers, Engaging Employees (Virtual).** More information is coming soon.

Oct. 12-15. **American Association of Tissue Banks (AATB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

Oct. 14-15. **International Protein Forum. Old Town Alexandria, Va.** [Registration](#) opens in July.

Oct. 25-28. **AABB Annual Meeting. San Diego, Calif.** More information is coming soon.

Oct. 26-29. **Blood 2025 and the ISBT 36th Regional Congress. Perth, Australia.** More information available [here](#).

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** [Registration](#) is open. More information available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Vice President of Technical Operations (Oklahoma City, OK). Our Blood Institute is looking for a **VICE PRESIDENT OF TECHNICAL OPERATIONS** who will provide strategic planning, operational management, budgeting, and leadership to the OBI and provide technical and leadership support to the Testing Lab, Quality

Control Lab, Manufacturing Operations, Logistics/Inventory Management, and Technical Operations Systems departments. Overseeing the day-to-day operations, implementing business plans, managing the department's P&L, and fostering high performance, customer-oriented

(continued on page 10)

POSITIONS (continued from page 9)

culture. Successful applicants must have a Bachelor of Science degree in Medical Technology and a Master's degree is strongly preferred. Position requires ASCP certification as a Medical Technologist and Specialist in Blood Banking is preferred. Position requires a minimum of ten years progressive management in a related medical industry. **Salary Range:** Competitive salary with excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. **How to apply:** <https://obi.org/about/careers/>

Vice President, CFO. LifeStream Blood Bank, headquartered in San Bernardino, California, an independent blood center serving 80 hospitals in six counties in Southern California is seeking a VP, CFO. Reporting to the President/CEO, the preferred candidate is one who has demonstrated successful leadership in other blood centers or healthcare related organizations. The successful candidate must possess strong strategic planning skills to navigate a competitive environment and strong interpersonal and communication skills to develop strong business partner relationships as well as within the organization. The CFO is directly responsible for all financial systems and functions of the organization and ensures legal and regulatory compliance for all accounting and financial reporting functions. The CFO participates as a member of the organization's Leadership and Executive Teams. Minimum seven years' progressive management experience is required. Bachelor's degree in accounting or other business-related field required with CPA and/or MBA or other relevant specialty preferred. Experience in not-for-profit healthcare setting; strong experience managing contracts, and good working knowledge and relationship with industry trade associations is preferred. Competitive salary, relocation package and excellent benefits. Please submit cover letter, resume and salary requirements to Judy Taylor, VP Human Resources at taylorju@LStream.org, and/or to submit your application click here: [APPLY HERE](#). The deadline for applications is **April 25, 2025**.

Technical Director, Manufacturing & Distribution. Mississippi Blood Services (MBS) is seeking a dynamic and flexible Technical Director to join our team. Since 1979, MBS has been committed to making a difference in the lives of patients in Mississippi hospitals. We offer an excellent working environment and great benefits. The ideal candidate will be confident, self-disciplined, and innovative, with strong problem-solving skills. Responsibilities include overseeing seroconversion look-back investigations, liaising with hospital labs, mentoring team members, ensuring compliance with FDA and regulatory guidelines, administering patient antibody letters, managing lab records, and assisting with inspections. A bachelor's degree and MT(ASCP) certification are required; MT(ASCP)BB or SBB preferred. This role requires flexibility, leadership, and the ability to work in

a fast-paced environment. If you're ready to make a meaningful impact, visit www.msblood.com to apply online.

Director, Quality Assurance/Regulatory Affairs. Hoxworth Blood Center (HBC) was founded in 1938 and serves more than 30 hospitals in 18 counties in Ohio, Kentucky, and Indiana. Annually, HBC collects more than 100,000 units of blood from local donors to help save the lives of patients in area hospitals. HBC is located within the University of Cincinnati (UC), College of Medicine, and is seeking a full-time Director, to oversee and direct the coordination of quality assurance and regulatory compliance for the collection, manufacture, storage and distribution of licensed and unlicensed blood and blood components, and for the testing of donor and patient samples. **Essential Functions:** Direct the coordination of regulatory compliance with the Food & Drug Administration (FDA), e.g., review of changes to regulations & guidance documents, submission of biological product deviation reports & response to observations/findings from FDA inspections. Support the Division Director in the preparation of license applications, annual report of minor changes & correspondence with the FDA. Manage the quality programs for maintaining applicable licensure and accreditation, e.g. internal and external audits, supplier qualifications, change control, deviation management, document control and record retention. **Minimum Requirements:** Bachelor's Degree and seven (7) years' experience. [Click HERE for the full job description and apply.](#) EOE

Executive Director – Enterprise IT Applications. Join us at New York Blood Center Enterprises (NYBCe). The Executive Director - Enterprise IT Applications opportunity provides leadership and strategic oversight for the enterprise portfolio of software application solutions, including Solutions analysis and recommendations, Development and planning, Configuration and maintenance, Testing and quality assurance, Deployment and implementation, and Ongoing maintenance and life cycle management. Serves as a member of enterprise IT leadership for the ongoing strategic direction, monitoring, evaluation, and quality assurance of enterprise IT applications. Responsibilities: Strategic IT Leadership & Governance, **Enterprise IT Application Management, Project & Vendor Management, IT Team Leadership & Development, Operational Support & Quality Assurance.** **Education:** Bachelor's degree in computer science, information systems or related field. **Experience:** 10 years of IT leadership experience in enterprise software applications, preferably in healthcare or a related industry. Proven experience in project management, vendor negotiations, and IT governance. Prior experience managing supervisory/managerial teams. **Locations:** Candidates must be able to report into one of the following NYBCe locations: Rye, New York; Kansas City,

(continued on page 11)

POSITIONS (continued from page 10)

Missouri; St. Paul, Minnesota; Providence, Rhode Island, and Newark, Delaware. For applicants who will perform this position in New York City or Westchester County, the proposed annual salary is \$225,000.00p/yr. to \$245,000.00p/yr. Please click [here](#) to view the full job description and apply.

Associate Medical Director/Medical Director (Versiti Blood Center of Ohio). Serve as the physician face of Versiti and Versiti Ohio, translating complex medical issues to educate other physicians, support staff and the public. Opportunities in educational initiatives and clinical/applied research are available within Versiti and with our affiliated health systems. As part of the Versiti physician team you will have the opportunity to participate in clinical research projects with investigators at our world-renowned diagnostic laboratory and blood research institute. Joining our Medical Science Institute transfusion medicine physician team will provide you with a uniquely diverse and collaborative experience. Requirements: MD or DO Degree. Board certified/eligible in Blood Banking/Transfusion Medicine. At least three years of experience in blood center/transfusion medicine practice preferred. Licensed or eligible for an Ohio and Indiana; other state licenses may be required. Driver's License in good standing. Please click [here](#) to read the full job description and apply. 💧